Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. COF
6. SMCI
7. GOOGL
8. RTX
9. TSLA
10. UAL

Go back to Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

October 2, 2026 11:15 AM EDT

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a potential new oral systemic therapy for adults with nonsegmental vitiligo

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.

In the two studies, TRANQUILLO 2 and TRANQUILLO, LITFULO 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation... More